Senti Biosciences Holdings (SNTI) Current Deferred Revenue (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Current Deferred Revenue of $43000.0 for Q4 2025, down 73.78% quarter-over-quarter from $164000.0 in Q2 2023.
Senti Biosciences Holdings (SNTI) Current Deferred Revenue (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $43000.0 for Q4 2025.
- In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $43000.0; the TTM figure through Dec 2025 stood at $43000.0 (changed N/A YoY), while the FY2025 annual figure was $43000.0, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $43000.0, down from $164000.0 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.7 million in Q4 2021, with the low at $43000.0 in Q4 2025.
- The 4-year median for Current Deferred Revenue is $407000.0 (2023), against an average of $571571.4.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue sank 51.75% in 2022, then plunged 80.31% in 2023.
- Senti Biosciences Holdings' Current Deferred Revenue stood at $1.7 million in 2021, then tumbled by 51.75% to $799000.0 in 2022, then tumbled by 79.47% to $164000.0 in 2023, then slumped by 73.78% to $43000.0 in 2025.
- Business Quant data shows SNTI's Current Deferred Revenue at $43000.0 in Q4 2025, $164000.0 in Q2 2023, and $407000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 43,000.00 |
| Jun 30, 2023 | 164,000.00 |
| Mar 31, 2023 | 407,000.00 |
| Dec 31, 2022 | 799,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 833,000.00 |
| Dec 31, 2021 | 1.66 Mn |